---
title: "广西梧州中恒集团获得中国批准用于治疗胸部和术后疼痛的药物"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/257850525.md"
description: "（MT Newswires）-- 根据周四在上海证券交易所的文件，中国医疗产品管理局批准了广西梧州中恒（SHA:600252）的硝苯地平片和酮咯酸托瑞米芬注射液。文件指出，硝苯地平片适用于心绞痛或胸痛，而酮咯酸托瑞米芬注射液适用于术后镇痛。周四下午交易中，股价下跌了 1%"
datetime: "2025-09-18T07:10:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257850525.md)
  - [en](https://longbridge.com/en/news/257850525.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257850525.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/257850525.md) | [繁體中文](https://longbridge.com/zh-HK/news/257850525.md)


# 广西梧州中恒集团获得中国批准用于治疗胸部和术后疼痛的药物

(MT Newswires) -- China's medical product administrator approved Guangxi Wuzhou Zhongheng's (SHA:600252) nicorandil tablets and ketorolac tromethamine injection, according to a Thursday filing with the Shanghai bourse.

The nicorandil tablets are indicated for angina pectoris or chest pain, while the ketorolac tromethamine injection is indicated for post-operative pain relief, the filing said.

Shares fell 1% during afternoon trading on Thursday.

### 相关股票

- [中恒集团 (600252.CN)](https://longbridge.com/zh-CN/quote/600252.CN.md)

## 相关资讯与研究

- [中兴通讯拟派发末期股息每 10 股 4.11 元](https://longbridge.com/zh-CN/news/278106497.md)
- [中国能建西北院刘增强拜访国家电投集团国际能源有限公司](https://longbridge.com/zh-CN/news/278021367.md)
- [含华量拉爆，昊铂 A800 掀桌子了](https://longbridge.com/zh-CN/news/278125294.md)
- [恒瑞医药：阿得贝利单抗注射液、SHR-8068 注射液获得药物临床试验批准通知书](https://longbridge.com/zh-CN/news/278070156.md)
- [雷军：料 5 年内限定场所可实现真正无人驾驶](https://longbridge.com/zh-CN/news/278024164.md)